Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China
· Delayed Price · Currency is CNY 48.17
-1.35 (-2.73%)
Apr 29, 2026, 3:04 PM CST
Betta Pharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 441.16 | 305.33 | 402.57 | 348.03 | 145.42 | 383.07 | Upgrade
|
| Depreciation & Amortization | 550.76 | 550.76 | 371.97 | 303.49 | 253.7 | 174.46 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.38 | -0.38 | 0.59 | 0.01 | -88.61 | -0.07 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.01 | 0.01 | 28.05 | 1.07 | 3.01 | 0.03 | Upgrade
|
| Loss (Gain) From Sale of Investments | 79.33 | 79.33 | 40.97 | 13.67 | 20.62 | -15.96 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.2 | -0.2 | -6.29 | 5.43 | 1.44 | - | Upgrade
|
| Other Operating Activities | -100.97 | 68.79 | 28.44 | 37.19 | 166.66 | 16.53 | Upgrade
|
| Change in Accounts Receivable | -290.9 | -290.9 | 156.53 | 174.2 | -198.29 | -181.6 | Upgrade
|
| Change in Inventory | -91.59 | -91.59 | 37.42 | 44.67 | -78.85 | -104.73 | Upgrade
|
| Change in Accounts Payable | 256.98 | 256.98 | -95.11 | 14.71 | -9.1 | 205.07 | Upgrade
|
| Change in Other Net Operating Assets | 49.42 | 49.42 | -57.13 | -16.46 | 132.53 | 75.97 | Upgrade
|
| Operating Cash Flow | 877.33 | 911.26 | 911.17 | 914.23 | 306.74 | 526.63 | Upgrade
|
| Operating Cash Flow Growth | -8.75% | 0.01% | -0.33% | 198.05% | -41.75% | -18.48% | Upgrade
|
| Capital Expenditures | -775.77 | -616.68 | -827.59 | -1,096 | -1,011 | -758.38 | Upgrade
|
| Sale of Property, Plant & Equipment | -0.01 | 0.08 | 0.14 | 22.21 | 0.69 | 0.24 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | -190.36 | Upgrade
|
| Investment in Securities | -311.23 | -311.26 | -174.24 | -431.65 | -314.49 | -33.62 | Upgrade
|
| Investing Cash Flow | -1,087 | -927.87 | -1,002 | -1,505 | -1,324 | -982.13 | Upgrade
|
| Long-Term Debt Issued | - | 917.78 | 644.75 | 1,890 | 1,036 | - | Upgrade
|
| Long-Term Debt Repaid | - | -820.87 | -663.76 | -515.82 | -8.77 | -6.88 | Upgrade
|
| Net Debt Issued (Repaid) | 206.96 | 96.91 | -19.01 | 1,374 | 1,027 | -6.88 | Upgrade
|
| Issuance of Common Stock | 92.17 | 92.17 | - | 60.79 | 53.78 | 76.7 | Upgrade
|
| Common Dividends Paid | -147.33 | -150.76 | -150.87 | -110.28 | -139.52 | -137.64 | Upgrade
|
| Other Financing Activities | -69.97 | -64.5 | -21.5 | -716.49 | - | -27.73 | Upgrade
|
| Financing Cash Flow | 81.83 | -26.18 | -191.38 | 608.19 | 941.52 | -95.56 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.71 | 1.08 | 1.59 | 3.74 | 15.38 | -2.9 | Upgrade
|
| Net Cash Flow | -127.13 | -41.7 | -280.31 | 20.71 | -60.7 | -553.96 | Upgrade
|
| Free Cash Flow | 101.57 | 294.58 | 83.58 | -181.79 | -703.8 | -231.75 | Upgrade
|
| Free Cash Flow Growth | -60.14% | 252.46% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 2.72% | 8.16% | 2.89% | -7.40% | -29.61% | -10.32% | Upgrade
|
| Free Cash Flow Per Share | 0.24 | 0.70 | 0.20 | -0.43 | -1.69 | -0.56 | Upgrade
|
| Cash Income Tax Paid | 310.14 | 262.97 | 116.65 | 94.58 | 111.5 | 152.36 | Upgrade
|
| Levered Free Cash Flow | -310.85 | -223.17 | -217.99 | -963.4 | -121.69 | -202.98 | Upgrade
|
| Unlevered Free Cash Flow | -265.56 | -175.58 | -189.56 | -929.06 | 0.69 | -193.12 | Upgrade
|
| Change in Working Capital | -92.37 | -92.37 | 44.88 | 205.34 | -195.49 | -31.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.